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Abstract Monoclonal anti-rat thyrotropin-releasing hormone
(TRH) receptor (TRHR)-specific antibodies (mAb) were gener-
ated by immunization with synthetic peptides of rat TRHR
partial amino acid sequences; one (TRHR01) was directed
against a sequence (84^98) in the extracellular portion of the rat
TRHR reported to be constant among different species, including
man, and the second (TRHR02) recognizes the C-terminal region
sequence 399^412. In lysates from GH4C1 cells, a clonal rat
pituitary cell line, both mAb recognize the TRHR in Western
blot analysis, and TRHR02 immunoprecipitates the TRHR.
Incubation of GH4C1 cells with the mAb causes a fluorescence
shift in fluorescence-activated cell sorting analysis. The cells
were stained specifically by both mAb using immunocytochem-
ical techniques. Furthermore, TRHR01 is agonistic in its ability
to trigger Ca2 flux, and desensitizes the TRH receptor. We
tested for TRHR in several rat organs and found expression in
lymphoid tissues. TRHR01 recognizes the human TRHR, and
analysis of human peripheral blood lymphocyte and tonsil-
derived leukocyte populations showed receptor expression in non-
activated and phytohemagglutinin-activated T and B cells.
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1. Introduction
Thyrotropin-releasing hormone (TRH) is the ¢rst hypo-
physiotropic hormone whose structure was elucidated and
chemical synthesis achieved [1,2]. TRH was discovered in
the hypothalamus and characterized for its ability to stimulate
pituitary thyrotropin secretion; thereafter, it was identi¢ed
in several extrahypothalamic brain structures and in other
organs and tissues [3]. TRH receptors (TRHR) have been
studied extensively (for a review, see [4]). TRH acts via the
phosphatidylinositol-calcium-protein kinase C transduction
pathway, although the existence of other e¡ectors has been
claimed, including adenylyl cyclase [5]. Evidence [6,7] is con-
sistent with the fact that Gq=11 proteins [8,9] couple the TRHR
to a phospholipase C that hydrolyzes phosphatidylinositol
4,5-diphosphate, although some experimental data strongly
suggest that other G proteins couple TRHR to di¡erent en-
zymatic systems that may act as TRH transducers [10^13].
cDNA cloning from mouse thyrotropic cells [14] and rat pi-
tuitary-derived clonal cell strains GH4C1 and GH3 [15,16]
showed that the TRHR belongs to the seven transmem-
brane-spanning G protein-coupled membrane receptor family.
Two receptor isoforms generated by alternative splicing have
been identi¢ed [17]. Although considerable information has
accumulated on TRHR function, and speci¢c residues have
been implicated in hormone binding [18^22], for a complete
understanding of TRHR biology, improved knowledge is nec-
essary of the molecular mechanisms involved in receptor reg-
ulation and in its interaction with transducers.
We generated TRHR-speci¢c monoclonal antibodies (mAb)
by immunizing mice with synthetic peptides of amino acid
sequences in the ¢rst extracellular loop (84^98) and the intra-
cellular C-terminal region (399^412) of the rat TRHR. Here
we describe the production and characterization of these
mAb, as well as a functional analysis based on their ability
to mimic TRH activity. We analyzed receptor expression in
rat lymphoid organs by Western blot; taking advantage of the
cross-reactivity with the human sequence, we studied TRHR
in human peripheral blood mononuclear cells (PBMC) as well
as tonsil cells and show its expression in unstimulated and
phytohemagglutinin (PHA)-activated T and B cells.
2. Materials and methods
2.1. Immunization and cell fusions
Two peptides of rat TRHR amino acid sequences deduced from the
large isoform cDNA [16] were synthesized on an automated peptide
synthesizer (AMS422 Abimed, Langefeld, Germany); they correspond
to the linear sequences 84^98 (TDSIYGSWVYGYVGC) and 399^412
(CTYGYSLTAKQEKI). The peptides were keyhole limpet hemocya-
nin (KLH)-conjugated (Pierce, Rockford, IL, USA) and BALB/c mice
immunized as described [23].
Spleen and/or lymph node cells from immunized mice were fused
with the P3X63-Ag8.653 myeloma cell line (CRL 1580, American
Type Culture Collection, Manassas, VA, USA) following standard
protocols [24,25]. Supernatants were tested for antibodies in en-
zyme-linked immunoassays (EIA), and positive hybridomas were
cloned.
2.2. EIA and isotype determination
EIA were performed essentially as described [26], using synthetic
peptides (3 Wg/ml in PBS, 100 Wl/well) adsorbed to 96-well plates
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(Maxisorb, Nunc, Denmark). Antibody isotypes were determined in
EIA using peroxidase (PO)-labeled subclass-speci¢c antisera (ICN,
Irvine, CA, USA).
2.3. Stable transfection and cell culture
Rat TRHR cDNA (large isoform) subcloned into the pLTR-neoE
eukaryotic expression vector was expressed in NIH-3T3 cells (CRL-
1658, ATCC). Cells were cultured in Dulbecco’s modi¢ed Eagle:
Ham’s F-12 medium (1:1 mixture, Sigma Chemicals, St. Louis,
MO, USA) containing phenol red, 0.13% NaHCO3, 10% FBS and
penicillin/streptomycin. For transfection experiments, trypsin-treated
con£uent cells were plated at a 1:15 dilution in 100 mm diameter
culture dishes. After 12^16 h, cells were transfected using a standard
calcium phosphate coprecipitation protocol [27] at 30 Wg of DNA/
dish, incubated for 18^24 h, trypsin-treated and replated in selective
medium containing 0.8 mg/ml geneticin (G-418, Gibco BRL, Paisley,
UK). TRHR expression was con¢rmed and quanti¢ed after 3 weeks
of culture in selective medium, following [3H]methyl-histidyl-TRH
(Dupont NEN, Boston, MA, USA) binding to transfected cells
(data not shown). GH4C1 cells (CCL-82.2, ATCC) were grown in
monolayer culture in Ham’s F10 medium with 10% FBS [28].
2.4. Flow cytometry analysis
GH4C1 T cells (2U105/100 Wl) were stained as described [29] with
anti-TRHR mAb or a mouse isotype-matched control mAb, mIgM
(1 Wg/50 ml/well for 60 min, 4‡C). When necessary, cells were permea-
bilized with 100 Wl of 70% ethanol for 10 min at 4‡C before staining.
The anti-human growth hormone receptor mAb hGHR05 [29] was
used as an isotype-matched control.
Human peripherla blood lymphocytes (PBL) or tonsil-derived lym-
phocytes were puri¢ed by Ficoll-Paque (5.7 g/l, Pharmacia) and acti-
vated with PHA (0.5%; Difco, Detroit, MI, USA), or ionomycin
(1 WM; Sigma) for 5 days at 37‡C, 5% CO2 in the presence of human
interleukin-2 (IL-2) (rIL-2; Ho¡mann-La Roche, Nutley, NJ). Hu-
man PBL or tonsil-derived cells were stained with biotin-labeled
anti-TRHR mAb and streptavidin-FITC or -phycoerythrin (PE), si-
multaneously with PE- or FITC-labeled anti-human leukocyte di¡er-
entiation markers for B (CD19, Coulter) or T cells (CD4 and CD8,
Coulter). Double staining of cells was determined as above.
2.5. Immunoprecipitation, SDS-PAGE and Western blot analysis
Cells (1U107) were centrifuged and resuspended in 100 Wl of lysis
bu¡er (50 mM Tris-HCl, pH 7.6, 1% Nonidet P-40, 250 mM NaCl,
0.5 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate and a
cocktail of protease inhibitors). After incubation (20 min, 4‡C), sam-
ples were centrifuged (15 000Ug, 15 min, 4‡C) and the pellet dis-
carded. Protein extracts (SF) were separated in 12.5% SDS-PAGE
[30] and transferred to nitrocellulose membranes for Western blot
analysis as described [29].
Immunoprecipitation was performed as previously described [31].
Brie£y, SF fractions were precleared by incubation with anti-mouse
IgM-agarose (20 Wg; Sigma) for 60 min at 4‡C and centrifugation
(15 000Ug, 1 min), then immunoprecipitated with mAb TRHR02
(5 Wg/sample) for 90 min at 4‡C, followed by anti-mouse IgM-agarose
(20 Wg, 60 min, 4‡C). Samples were centrifuged (15 000Ug), agarose
pellets were washed twice with lysis bu¡er, three times with 50 mM
Tris-HCl, pH 7.6, resuspended in Laemmli bu¡er and electropho-
resed.
2.6. Calcium determination
Changes in intracellular calcium concentration were monitored us-
ing the £uorescent probe Fluo-3AM (Molecular Probes, Eugene, OR,
USA). NIH-3T3 cells transfected with cDNA encoding the rat TRHR
and pLTR-neoE-transfected control cells were suspended in RPMI
containing 10% FBS and 10 nM HEPES, then incubated with 12
Wl/106 cells of Fluo-3AM (300 WM in DMSO) for 30 min at 37‡C
as previously described [31].
2.7. Immunocytochemistry
GH4C1 and pLTR-neoE-transfected NIH-3T3 cells were cultured
on glass coverslips, then ¢xed with 4% paraformaldehyde and 0.1%
glutaraldehyde in phosphate bu¡er (0.1 M, pH 7.4) for 30 min at
room temperature. After three washes with PBS, cells were incubated
in 0.1% sodium borohydride for 30 min to quench free aldehyde
groups, permeabilized with 0.02% Triton X-100 in PBS for 30 min
and incubated with 0.2% gelatin in PBS to prevent non-speci¢c anti-
body binding. Cells were incubated alone or with antibody (TRHR01,
TRHR02 or hGHR05, 1:5 supernatant dilution) in PBS for 1 h at
room temperature, and immunoperoxidase stained using the avidin-
biotin-PO complex (Vectastain Kit, Vector Laboratories, Burlingame,
CA, USA). The chromogen (0.06% diaminobenzidine in 0.03% H2O2)
was incubated for 5^10 min, depending on microscopic evaluation of
wet-mount coverslips.
2.8. Animal studies
Normal adult male Wistar rats (200^250 g) were used to study
TRHR in lymphoid tissues. Rats were killed by decapitation, and
organs (thymus, mesenteric lymph nodes and spleen) were placed in
dry ice and maintained at 380‡C until processed. They were then
placed in lysis bu¡er as for immunoprecipitation assays and homog-
enized using a Polytron (Kinematica A). Homogenates were centri-
fuged (20 000Ug, 20 min, 4‡C) and the supernatant maintained at
380‡C until electrophoresis and blotting were performed. Protein
loading was controlled using a protein detection kit (Pierce). Electro-
phoresis and Western blots were performed as above.
3. Results
3.1. Characterization of TRHR-speci¢c mAb
Spleen and lymph node cells from two mice immunized
with synthetic peptides of rat TRHR amino acid sequences
84^98 and 393^412 (found in the ¢rst extracellular loop and
the intracellular C-terminal region, respectively) [16] were
fused with the P3X63-Ag8.653 myeloma cell line. After cul-
ture and screening, one hybrid producing mAb to the ¢rst
extracellular loop (TRHR01) and another producing mAb
to the C-terminal region (TRHR02) were selected for further
stabilization and characterization. Isotype determinations
showed that both mAb are IgM, U.
To determine mAb speci¢city, binding studies were per-
formed using £uorescence-activated cell sorting analysis. A
signi¢cant £uorescence shift was observed in intact rat pitui-
Fig. 1. mAb binding to the GH4C1 line. GH4C1 cells in exponential
growth, intact (GH4C1, upper panels) or permeabilized with ethanol
(GH4C1+EtOH, lower panels), were stained with mAb TRHR01,
TRHR02 or mIgM (hGRH05) as indicated, followed by GAM-
FITC as described in Section 2. Histograms show £uorescence in-
tensity of mAb staining (x axis) versus relative cell number (y axis),
compared with that of an isotype-matched control mAb. The ¢gure
depicts one representative experiment of ¢ve performed.
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tary GH4C1 cells incubated with TRHR01, whereas no bind-
ing was detected using TRHR02 or a control mAb (Fig.
1A,B). When cells were ethanol permeabilized, both
TRHR01 and TRHR02, but not the control mAb, induced
a £uorescence shift (Fig. 1C,D). Both mAb recognize a spe-
ci¢c band in Western blot analysis of GH4C1 cell lysates (not
shown). TRHR02 immunoprecipitates a GH4C1 cell lysate
protein that is recognized in Western blot analysis by both
mAb (Fig. 2).
To ensure the speci¢city of these anti-rat TRHR mAb,
NIH-3T3 cells were transfected with cDNA encoding the rat
TRHR subcloned into the pLTR-neoE eukaryotic expression
vector. Receptor expression was con¢rmed and quanti¢ed us-
ing [3H]methyl-TRH binding analysis, as described in Section
2. Transfected cell lysates were used to con¢rm mAb reactivity
in Western blot analysis ; TRHR02 speci¢cally recognized a
single band not present in pLTR-neoE-transfected cells (Fig.
3).
To further test speci¢city, GH4C1 cells were immunostained
with TRHR01 (Fig. 4A) and TRHR02 (Fig. 4B). No staining
was observed in ¢broblasts not expressing TRHR, or in
GH4C1 cells in which control mAb hGHR05 was used (not
shown). The immunoperoxidase end product was located at
the cell periphery, as a di¡use reaction distributed throughout
the cytoplasm and as an intense granular precipitate within
the cytoplasm (Fig. 4C,D). No nuclear staining was seen.
Distribution of the immunoreactive material was similar using
both mAb, but was fainter in TRHR02 staining of non-per-
meabilized cells, concurring with the intracellular localization
of the epitope (data not shown).
3.2. TRHR01 mimics TRH-induced Ca2+ mobilization
We analyzed the e¡ect of the mAb on TRH-induced Ca2
mobilization. Fluo-3AM-loaded NIH-3T3 cells transfected
with rat TRHR cDNA were preincubated with puri¢ed
mAb before TRH stimulation, resulting in blockage of
TRH-promoted Ca2 mobilization by mAb TRHR01. No ef-
fect was seen when cells were preincubated with control or
TRHR02 mAb (not shown). We also tested whether the mAb
has intrinsic TRH-like activity, as TRH function blockade in
Ca2 mobilization assays could be due to either agonist or
antagonist activity leading to receptor desensitization. Stimu-
lation with mAb TRHR01 induces a rapid, transient increase
in Ca2 concentration and desensitizes the TRHR in response
to TRH; TRH stimulation also induces receptor desensitiza-
tion to the TRHR01 mAb (Fig. 5A^D). As expected, pLTR-
neoE-transfected 3T3 cells did not respond to either ligand
(TRH of TRHR01) (Fig. 5E,F). Fluo-3AM loading equiva-
lence was determined by Ca2 mobilization in response to the
calcium ionophore ionomycin (5 Wg/ml). The activity of mAb
TRHR01, speci¢c for the ¢rst extracellular loop (amino acids
84^98) of the TRHR, thus indicates an important role for this
region in ligand-induced biological activity.
3.3. The TRHR is expressed in T and B cells and in lymphoid
organs
Recent evidence indicates a possible role for TRH in the
development of certain lymphoid cells [32], and indirect data
support the presence of the TRHR in thymocytes [33] ; we
thus tested for TRHR in extracts of rat lymphoid organs.
Electrophoresis and Western blot of these extracts with
TRHR02 showed a speci¢c protein corresponding to the rat
TRHR (Fig. 6) in thymus, mesenteric lymph nodes and spleen
extracts, whereas no reaction was observed in control liver
extracts.
The speci¢city of these mAb and the cross-reactivity of
TRHR01 with human TRHR, as the 84^98 sequence is also
found in the human receptor, led us to test for TRHR ex-
pression in various leukocyte populations. Resting and PHA-
or ionophore-activated PBMC were analyzed in £ow cytom-
etry by double-color staining using biotin-labeled TRHR01 in
conjunction with speci¢c B and T cell markers. Based on these
assays, TRHR is expressed in PBMC-derived B (30% of
CD19 cells) and T cells (40% CD4 and 18% CD8). Ton-
sil-derived B (70% of CD19 cells) and T cells (30% CD4
and 8% CD8 cells) also express the TRHR (Fig. 7). TRHR
expression in B and T cells is unaltered following PHA acti-
vation, indicating constitutive TRHR expression in these cells
(Fig. 7).
Fig. 2. Immunoprecipitation of GH4C1 cell lysates by TRH02.
GH4C1 cell lysates (1U107 cells) were immunoprecipitated using 5
Wg/ml of TRHR02. The pellet was immunoblotted using TRHR02
(10 Wg/ml; lane 1), TRHR01 (10 Wg/ml; lane 2) and isotype-matched
mAb (10 Wg/ml; lane 3). Other bands correspond to the heavy and
light chains of the immunoprecipitating immunoglobulin. A repre-
sentative autoradiogram is shown. The arrow indicates the position
of rat TRHR.
Fig. 3. Western blot analysis of NIH-3T3 cells transfected with
cDNA encoding the rat TRHR. NIH-3T3 cells transfected with the
cDNA encoding the rat TRHR (lane 1) or pLT-neoE-transfected
NIH-3T3 cells (lane 2) (1U107 cells) were lysed and immunoblotted
as described in Section 2 using TRHR02 (10 Wg/ml). Protein loading
was controlled using a protein detection kit (Pierce). Arrow shows
the position of rat TRHR.
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4. Discussion
Study of the biochemical characteristics of TRHR has been
hampered by the lack of appropriate reagents. Detergent-
based analysis failed mainly because detergents disrupt recep-
tor interaction with the labeled ligand, and as the ligand could
not be covalently cross-linked to its receptor (data not
shown). Straub et al. [10] nevertheless established the structure
of the murine TRHR based on its cDNA sequence; this struc-
ture, corresponding to that of a G protein-coupled receptor
(GPCR), has been con¢rmed by various groups and reported
for several species. Monoclonal antibodies have been widely
employed for the characterization and biochemical analysis of
several receptors, including those of the GPCR superfamily
[34]. Here we describe the production and characterization of
two mAb that speci¢cally bind TRHR in GH4C1 pituitary
cells, and analyze their function based on their ability to
mimic TRH activity.
Synthetic peptides of rat TRHR sequences were chosen as
immunogens as they permit preselection of receptor regions of
interest. Several sequences were chosen in a ¢rst approach,
based on various criteria: ¢rst, on the amino acid sequence
analysis, which allows selection of receptor regions that are
species-speci¢c or are present in other species, enabling gen-
eration of speci¢c or potentially cross-reactive mAb. The sec-
ond criterion was for sequences that include amino acids im-
plicated in ligand binding, which would be useful in
generating mAb that might a¡ect TRH activity, and third,
sequence-based structural requirements that might give rise
to peptides that resemble receptor conformations. These cri-
teria do not ensure the desired immune response, however, as
seen for immunogens including sequences from the TRHR
second and third extracellular loops, which failed to elicit
antibody responses in our hands. The amino acids in these
two loops are important in the initial interaction of TRH with
its receptor [35]. Production of mAb with possible agonist
activity should nonetheless not be restricted to sequences
known to be involved in the ligand binding site. It has been
shown that mAb against epitopes not involved in the ligand
binding site of the growth hormone receptor can mimic
growth hormone (GH) activity by stabilizing an active con-
formation of this receptor [29]. In vitro, TRHR01 recognizes a
peptide corresponding to a sequential epitope in the ¢rst ex-
tracellular loop (amino acid sequence 84^98), a sequence also
present in the human TRHR. TRHR02 binds an epitope in
the intracellular C-terminal region of the rat TRHR (amino
acids 399^412).
In several assays, including £ow cytometry, Western blot,
immunoprecipitation and immunohistochemistry, TRHR01
and TRHR02 bind speci¢cally to the rat GH4C1 cell line,
which expresses a large number of TRHR copies. Consistent
with the intracellular location of the epitope recognized by
TRHR02, cell permeabilization is necessary to allow
TRHR02 interaction with the receptor in £ow cytometry as-
says. TRHR01 binding increases after permeabilization; this
treatment may improve exposure of the sequential epitope
recognized, or make accessible receptor molecules located in
other intracellular compartments.
Both TRHR01 and TRHR02 recognize a speci¢c band in
Western blot analysis of GH4C1 cell lysates; this band is also
detected by polyclonal antibodies from animals immunized
with other rat TRHR sequences (not shown). TRHR02 im-
Fig. 4. Immunocytochemistry of GH4C1 cells using TRHR01 and TRHR02. Immunostaining of GH4C1 cells using TRHR01 or TRHR02 is
shown in panels A and B, respectively. Note that there is a signi¢cant number of intensely stained cells, whereas others are weakly labeled.
High-power light micrographs show the di¡erential distribution of immunoreactive material in GH4C1 cells stained with TRHR01 (C) or
TRHR02 (D). The reaction is restricted to the cell periphery (small arrows), intense granular staining within the cytoplasm (open arrows) or
di¡use cytoplasmic immunoprecipitate (long arrows). A and B: magni¢cation, 340U ; C and D, 850U.
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munoprecipitated the same protein from GH4C1 cell lysates.
To demonstrate clearly the speci¢city of these mAb, NIH-3T3
cells were transfected with the cDNA encoding the rat TRHR.
The presence of functional membrane receptors was shown by
their ability to bind TRH, and by the response to TRH-pro-
moted Ca2 mobilization. TRHR01 stained the transfected
cells and TRHR02 recognized the same band in Western
blot analysis of cell lysates, whereas no recognition was ob-
served in pLTR-neoE-transfected 3T3 cells.
In ligand binding and receptor mRNA expression in oo-
cytes, Gautvik et al. [36,37] presented evidence for two
TRHR types in rat GH4C1 cells; in Southern blot hybridiza-
tion analysis of GH4C1 and GH3 cells, however, others found
a pattern consistent with a single gene copy [15,17]. Ligand
binding and Western blot analysis of GH4C1 cell lysates using
our mAb support the second hypothesis, corroborating the
existence of only one rat TRHR type.
The cloning and characterization of a novel subtype of rat
TRH receptor, rTRHR2, was recently described [38,39] ; this
receptor appears to be restricted to the central nervous sys-
tem, in particular to the sensory neurons of the spinothalamic
tract and the spinal cord dorsal horn. This new TRHR lacks
44 C-terminal amino acids of the classic TRHR (rTRHR1),
which include the epitope recognized by TRHR02. The
TRHR01 mAb recognizes the amino acid sequence TRHR1
(84^98), which has a high degree of identity with the corre-
sponding sequence in rTRHR2, indicating that this mAb may
recognize both subtypes.
The 19 amino acid C-terminal extension of the rat TRHR is
probably not critical for ligand binding or G protein coupling
[15,16] ; TRHR02 may thus be of use in determining whether
this sequence has a role in receptor regulation. As this mAb
immunoprecipitates the receptor, it may also serve to study
possible signal transduction molecule association to the
TRHR.
Speci¢c immunostaining was observed in GH4C1 cells in-
cubated with TRHR01 and with TRHR02. The di¡erence in
the expression level between permeabilized and non-permea-
bilized cells may indicate improved epitope exposure in the
ethanol-treated cells. Both antibodies recognize the TRHR
speci¢cally, as only cells expressing this receptor were reactive.
The location of staining at the cell periphery and plasma
membrane conforms with the location expected for a mem-
brane receptor. Intracytoplasmic staining may indicate intra-
cellular receptor pools in the processes of synthesis, endocy-
tosis and tra⁄cking [40^42]. Electron microscopy studies will
be necessary to elucidate the precise location of these TRHR
pools.
More important is the evidence that TRHR01 has agonistic
activity, mimicking TRH-promoted Ca2 mobilization and
evoking desensitization of the response to the natural ligand.
The same e¡ect occurs in the inverse experiment, in which
TRH desensitizes the cells in response to TRHR01. The e¡ect
is clearly speci¢c, since the isotype-matched control mAb
TRHR02, which recognizes an intracellular epitope, promotes
no e¡ect. Neither was any e¡ect observed for TRH or for
TRHR01 when Ca2 mobilization assays were performed in
pLTR-neoE-transfected NIH-3T3 cells, although they were
equally loaded with Fluo-3AM.
In the absence of other data mapping the TRHR residues
implicated in TRH binding, our data support a critical role
for amino acids 84^98 in TRHR activity. The e¡ect may be
due to direct interaction with the ligand binding epitope or to
the stabilization of an active receptor state. The latter case has
been shown in other receptors such as the human growth
hormone receptor (hGHR), for which a mAb that does not
compete for GH binding can stabilize an active hGHR con-
formation [29]. Our data suggest that regions other than those
previously implicated in TRH binding may also be important
Fig. 5. TRHR01 mAb promotes Ca2 mobilization and desensitizes
the TRH-induced response. NIH-3T3 cells transfected with cDNA
encoding the rat TRHR were loaded with Fluo-3AM and processed
as indicated in Section 2. Ca2 mobilization was induced with TRH
(1 Wg/ml), TRHR01 or TRHR02 (20 Wg/ml). TRH promotes Ca2
mobilization, and cells were desensitized to a second stimulation
(A). TRHR01 induces the same activity and desensitizes the cells to
a TRH challenge (B). TRHR02 has no e¡ect and does not modify
the TRH response (C). TRH also desensitizes the cell to a challenge
with TRHR01 (D). As a control, pLTR-neo-transfected NIH-3T3
cells were stimulated by TRH (E) or TRHR01 (F). Results are ex-
pressed as a percentage of the TRH-induced calcium response. The
¢gure depicts the results of one experiment representative of ¢ve
performed. Arrows depict the time of stimulus addition.
Fig. 6. TRHR is expressed in rat lymphoid organs. Thymus (lane
1), lymph nodes (lane 2), spleen (lane 3) and liver (lane 4) as a con-
trol, were homogenized and immunoblotted as described in Section
2 using TRHR02 (10 Wg/ml). Protein loading was controlled using a
protein detection kit (Pierce). The arrow shows the position of rat
TRHR.
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for ligand binding, for receptor activation, or for both. A
dichotomy between binding and activating regions has been
shown for other GPCR, as is the case for chemokine recep-
tors. Assays using chimeric chemokine receptors and mAb
suggest a two-step mechanism, indicating dissociation between
regions involved in ligand binding and activation [34,43,44].
The ¢nding of TRHR in lymphoid tissues and cells is also
interesting, and suggests an unknown role for this hypothala-
mic hormone in these cells. Studies in athymic mice indicate
that TRH and TSH signi¢cantly in£uence the development of
lymphoid cells associated with intestinal intraepithelial lym-
phocytes [45]. Data also support the presence of the TRHR
in thymocytes, as it has been shown that TRH promotes thy-
mic reconstitution in mice with anterior hypothalamic area
lesions [32]. Northern blot analyses have recently identi¢ed
TRHR mRNA in immune cells [33] ; the use of TRHR01
and TRHR02 extends this to the presence of the protein in
lymphoid organs, as well as in unstimulated and PHA-acti-
vated PBMC and tonsil-derived B and T cells. These ¢ndings
indicate constitutive TRHR expression in these cells and con-
¢rm previous data showing that activation does not a¡ect
TRHR mRNA levels in PBMC [33].
The mAb staining pattern described con¢rms an active role
for TRH in the immune system [46] and opens new perspec-
tives. Their speci¢city renders these mAb of considerable val-
ue for receptor localization analysis in tissues and cell lines, as
well as for studies of cell tra⁄cking, hormone binding-related
motifs, proteins associated following binding, and residues
implicated in receptor regulation. In view of the recent de-
scription of the novel TRHR subtype, new experiments are
in progress to determine whether these mAb will aid in dis-
secting the responses triggered by one or the other TRHR
type.
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